Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 10Breast Neoplasms 9Prostatic Neoplasms 7Multiple Myeloma 6Colorectal Neoplasms 5Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms by Site 2Mycoses 2Medication Adherence 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia 2Carcinoma, Transitional Cell 2COVID-19 2Adenocarcinoma 2Uveal Melanoma 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1

Interventions

Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Progressive Metastatic Castrate Resistant Prostate Cancer × Standard of Care × Clear all
NCT07206056 2026-06-03

TulmiSTAR-01

Novartis

Phase 1/2 Recruiting
188 enrolled
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡